Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2014 - KXNet.com - Bismarck/Minot/Williston/Dickinson-KXNEWS,ND

Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer



 

 

 

LONDON, June 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/drug_discovery/hormone_refractory_breast_cancer_global_clinical_trials_review_h1_2014.html

Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2014


Summary

GlobalData's clinical trial report, "Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2014" provides data on the Hormone Refractory Breast Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone Refractory Breast Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone Refractory Breast Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)


Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Hormone Refractory Breast Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Hormone Refractory Breast Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Hormone Refractory Breast Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Unaccomplished Trials of Hormone Refractory Breast Cancer 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Hormone Refractory Breast Cancer Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Hormone Refractory Breast Cancer 29
Jan 16, 2012: Researchers Report Combination Of Lapatinib And Trastuzumab May Provide Better Preoperative Breast Cancer Treatment 29
Nov 13, 2011: HDAC Inhibitor May Overcome Resistance To Common Breast Cancer Drug 29
Dec 27, 2006: ADVENTRX Initiates CoFactor Phase II Clinical Trial In Refractory Breast Cancer 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
F. Hoffmann-La Roche Ltd. 31
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 31
Neopharm Ltd. 32
Clinical Trial Overview of Neopharm Ltd. 32
NeoCorp GmbH 33
Clinical Trial Overview of NeoCorp GmbH 33
C. H. Boehringer Sohn AG & Co. KG 34
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 34
Bluefish Pharmaceuticals AB 35
Clinical Trial Overview of Bluefish Pharmaceuticals AB 35
Bioenvision Limited 36
Clinical Trial Overview of Bioenvision Limited 36
AstraZeneca PLC 37
Clinical Trial Overview of AstraZeneca PLC 37
AmpliMed Corporation 38
Clinical Trial Overview of AmpliMed Corporation 38
Clinical Trial Overview of Top Institutes / Government 39
Southeastern Cancer Study Group 39
Clinical Trial Overview of Southeastern Cancer Study Group 39
Jules Bordet Institute 40
Clinical Trial Overview of Jules Bordet Institute 40
Japan Breast Cancer Research Network 41
Clinical Trial Overview of Japan Breast Cancer Research Network 41
Masonic Cancer Center 42
Clinical Trial Overview of Masonic Cancer Center 42
Alberta Health Services 43
Clinical Trial Overview of Alberta Health Services 43
Emory University 44
Clinical Trial Overview of Emory University 44
National Cancer Institute 45
Clinical Trial Overview of National Cancer Institute 45
Five Key Clinical Profiles 46
Appendix 120
Abbreviations 120
Definitions 120
Research Methodology 121
Secondary Research 121
About GlobalData 122
Contact Us 122
Disclaimer 122
Source 123


List of Tables

Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Hormone Refractory Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Hormone Refractory Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Hormone Refractory Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Hormone Refractory Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Hormone Refractory Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Hormone Refractory Breast Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 23
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 24
Hormone Refractory Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 25
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 26
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 27
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 28
Hormone Refractory Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 31
Hormone Refractory Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Neopharm Ltd., 2014* 32
Hormone Refractory Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by NeoCorp GmbH, 2014* 33
Hormone Refractory Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 34
Hormone Refractory Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bluefish Pharmaceuticals AB, 2014* 35
Hormone Refractory Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bioenvision Limited, 2014* 36
Hormone Refractory Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 37
Hormone Refractory Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AmpliMed Corporation, 2014* 38
Hormone Refractory Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Southeastern Cancer Study Group, 2014* 39
Hormone Refractory Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Jules Bordet Institute, 2014* 40
Hormone Refractory Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Japan Breast Cancer Research Network, 2014* 41
Hormone Refractory Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2014* 42
Hormone Refractory Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Alberta Health Services, 2014* 43
Hormone Refractory Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 44
Hormone Refractory Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 45


List of Figures

Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Hormone Refractory Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Hormone Refractory Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Hormone Refractory Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Hormone Refractory Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Hormone Refractory Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 24
Hormone Refractory Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 25
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 26
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 27
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 28
GlobalData Methodology 121



Read the full report:
Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/drug_discovery/hormone_refractory_breast_cancer_global_clinical_trials_review_h1_2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
General information or questions:
kxinfo@kxnet.com

News:
Bismarck:
Phone: 701-223-9197
News Fax: 701-223-1985

News:
Minot:
Phone: 701-852-2104
News Fax: 701-838-1050
All content © Copyright 2000 - 2014 WorldNow and KXNET. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.